Global Viral and Non-Viral Vector Manufacturing Market 2022: Favorable Funding Scenario for Vector-Based Therapies | Rapid Uptake of Viral Vector to Develop Innovative Therapies
08 févr. 2022 04h18 HE
|
Research and Markets
Dublin, Feb. 08, 2022 (GLOBE NEWSWIRE) -- The "Global Viral and Non-Viral Vector Manufacturing Market: Focus on Vector Type, Application, Disease and Region - Analysis and Forecast, 2021-2031"...
Global Cell & Gene Therapy Markets, 2021-2022 & 2027 - New Product Approvals & Increasing Pipeline of Products & Prime Designation & Funding Support For CGT
07 févr. 2022 07h08 HE
|
Research and Markets
Dublin, Feb. 07, 2022 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The cell and gene...
Global Biobanking Market (2021 to 2027) - Featuring AstraZeneca, Biokryo and Lonza Among Others
03 févr. 2022 06h13 HE
|
Research and Markets
Dublin, Feb. 03, 2022 (GLOBE NEWSWIRE) -- The "Biobanking Market 2021-2027" report has been added to ResearchAndMarkets.com's offering. The biobanking market is anticipated to grow at a...
invIOs to present at upcoming conferences
03 févr. 2022 02h00 HE
|
invIOs GmbH
VIENNA, Austria, Feb. 03, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming...
Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer
31 janv. 2022 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
26 janv. 2022 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
OcyonBio Appoints Daniel Chang, CPA, MBA, CPMP, CPIM as Chief Financial Officer
25 janv. 2022 09h00 HE
|
OcyonBio (ocyonbio.com)
AGUADILLA, Puerto Rico, Jan. 25, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC announces it has appointed Daniel Chang Chief Financial Officer. OcyonBio is creating a contract development and manufacturing...
Global Viral Vectors for Cell Therapy Market Research Report 2022: Demographic Trends, New Developments, Cell and Gene Therapy Advancements, Company Performance Trends, M&As
19 janv. 2022 06h38 HE
|
Research and Markets
Dublin, Jan. 19, 2022 (GLOBE NEWSWIRE) -- The "Viral Vectors Market for Cell Therapy Market: Analysis and Opportunities" report has been added to ResearchAndMarkets.com's offering. All market data...
Global CAR T-cell Therapy Market (2021 to 2031) - Industry Analysis, Size, Share, Growth, Trends, and Forecasts
18 janv. 2022 06h58 HE
|
Research and Markets
Dublin, Jan. 18, 2022 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031" report has been added to...
OcyonBio Appoints Robert Salcedo as Chief Executive Officer
06 janv. 2022 16h00 HE
|
OcyonBio
AGUADILLA, Puerto Rico, Jan. 06, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC is creating cell and gene therapy partnership development and manufacturing organization (PDMO). OcyonBio will provide...